MindMaze, a company in neurotechnology, has unveiled MindLeap, the first thought-powered virtual and augmented reality system, back in 2015. The company secured $8.5 million in investment funding to accelerate the commercialization of its neurotechnology engine.
These funds will build on the company’s past work in medical technology, where it used no-latency virtual reality to speed recovery for patients with a variety of neurological impairments.
MindMaze, for example, helps stroke victims and amputees regain motor function by teaching them how to control robotic and virtual limbs. These amazing capabilities are possible thanks to the near-millisecond synchronization of large amounts of brain and body data.
MindMaze introduces its medical-grade technology to gamers. This allows them to feel and sense virtual reality, and unleash the power of their brain and body to control the games.
This technology unlocks a new era in neurorehabilitation, and gamification and provides unparalleled responsiveness by tapping into key neural signatures.
MindMaze’s medically-proven neurotechnology engine is the basis of the system. It detects and predicts brain activity and triggers immersive virtual experiences in real-time.
MindLeap combines neural sensing and embedded motion capture cameras to unleash the power of players’ brains to enhance gameplay and experiences both in virtual and augmented realities.
MindLeap is the fastest system on the market and will bring a new level to virtual reality performance.
MindLeap’s Neurotechnology Engine is now available to developers via an SDK, and to gamers via a new head-mounted display (HMD), that consists of the first-of-its-kind “NeuroGoggles”, and a 3D motion capture camera.
MindLeap created a new way for gamers to engage with and experience the gameplay in their favorite games. This includes not only seeing their avatars/bodies but also triggering events with their intent.
MindLeap enables neuro-powered immersive virtual or augmented reality on multiple platforms and games consoles, including XBOX and PlayStation.
MindMaze uses proprietary neuroscience paradigms to enable thought-driven gameplay mechanics without the use of a controller.
The HMD and wireless 3D camera allow for real-time mapping and movement of avatars. This allows for an instant response via virtual reality in gameplay, even on mobile and tablet devices.
MindMaze founder and CEO Dr. Tej Tadi says that the technology allows game developers to create responsive virtual games experiences. This further immerses gamers in the gameplay and provides opportunities for deeper engagement with customers.
MindMaze raised an additional 100 million in 2016
MindMaze secured commitments of $100 million in 2016 from the Hinduja Group. This 102-year-old global conglomerate has been investing since its early stages. Family offices also participated.
MindMaze also announced its pre-money valuation exceeding $1 billion. This will allow it to continue its track record of launching high-end, medical-grade neural virtual realities platforms.
MindMaze’s revolutionary platform for creating intuitive human-machine interfaces combines virtual and computer vision, neuroscience, artificial intelligence, and haptics.
This multisensory technology is the first of its kind and has been successfully commercialized for brain-injury survivors following strokes and brain injuries.
The company’s current regulatory approvals allow it to speed up placements in Europe and Asia. MindMaze’s platform is now available to more people through licensing in both the business-to-business and business-to-consumer spaces. This allows MindMaze to create mainstream experiences with virtual reality-optimized products.
MindMaze’s partnerships with Asian manufacturers and distributors allowed it to expand its technology into new verticals, while also consolidating its interests.
MindMaze’s success is evident in the healthcare sector where partnerships were formed for financing and leasing devices. MindMaze also has customer service centers in over 50 countries. MindMaze was able to access new markets and territories through these opportunities.
MindMaze is a group of thought leaders and industry experts who were attracted to the vision and milestones that the company has achieved in such a short time.
The advisory board is made up of top scientists and business leaders from major institutions and organizations such as Medtronic and Baxter, HBO, and Stanford University.
MindMaze continues to build on its past of providing clinical data and results to doctors and patients. MindMaze also brings emotion and human connection to immersive games, experiences, and games.
The platform was first tested in the healthcare sector in 2016. It is currently being used in the United States at key centers for cognitive and motor recovery.
MindMaze acquires NMI in 2018
MindMaze purchased Neuro Motor Innovations Corporation on November 28th, 2018. This acquisition was made with the goal of significantly improving recovery for patients with neurological diseases or injuries.
The acquisition combines neuroscience and a novel form of animation “neuroanimation” – to stimulate vast improvement of cognitive and motor functions, complements MindMaze’s approach to neuro-rehabilitation.
MindMaze also developed and commercialized NMI technology for a variety of neurological injuries and diseases. The immersive cognitive-motor experiences are also used to promote healthy aging and wellness.
It is evident that complex movements are crucial for executive cognitive function.
NMI was founded by Dr. John Krakauer (neuroscientist), Dr. Omar Ahmad (computer scientist), and Promit Roy (software architect) at The Kata Design Studio at The Johns Hopkins University Department of Neurology CEO Hoyt D Morgan.
MindMaze was granted a perpetual license to NMI technology and continued its relationship with Johns Hopkins. Dr. Krakauer was a Malone Professor at Hopkins’ School of Medicine, and the Malone Center for Engineering in Healthcare. He also served as MindMaze’s Chief Medical and Scientific Advisor.
MindMaze is now the creator of the first global platform from clinic to the patient for neurological therapy. It uses an intuitive mind/machine interface that instantly decodes brain and muscle signals.
MindMaze’s platform, which is based on neuroscience, mixed reality, and artificial intelligence, has been used in multiple industries. MindMotion was the first FDA-cleared neuro-rehabilitation product for Americans.
MindMaze partners with McLaren Racing for Real-time Driver Safety Initiative
McLaren Racing and MindMaze entered into an innovative partnership in 2019 for the Indianapolis 500.
In this technology partnership, the companies jointly designed and developed MindDrive, the next generation of safety- and performance platforms for motorsport. MindMaze’s brain-sensing technology has been awarded the prestigious MindMaze award.
The product can capture and transmit crucial neural signatures of the driver to a trackside medical team in real-time in the event that there is an accident. McLaren Racing can also use the technology to gain insight and data on driver performance and safety.
MindMaze and Mount Sinai Launched at Home Tele-Neurorehabilitation Program for Stroke Patients
On September 30th, 2020, MindMaze and Mount Sinai Health System, the largest academic medical system in New York City launched an innovative at-home tele-neurorehabilitation program for stroke patients, utilizing the FDA-cleared and CE-marked MindMotion GO(tm).
MindMaze’s mobile neurorehabilitation therapy system is the first of its kind. Patients can now continue their recovery at home by receiving virtual support from Mount Sinai’s Abilities Research Center (ARC). This initiative increases patient access to MindMotion GO.
It has been adopted by Mount Sinai’s Rehabilitation Innovation team since June 2020 in order to provide neurorehabilitation across all levels of care.
With the COVID-19 pandemic impacting all aspects of public health, including limiting patients’ access to important rehabilitation interventions, access to tele-neurorehabilitation has never been more essential.
Mount Sinai patients can use MindMaze’s digital gamified therapy program to seamlessly move from inpatient to outpatient rehabilitation. They can also continue their recovery at their home while still receiving the support and care of their physical therapists.
MindMotionGO is designed to help patients with acute or chronic stroke train for longer periods of time. It guides all body parts, including the trunk and upper limbs. This helps improve motor and task function.
MindMotion GO’s range of therapeutic games allows clinicians to create personalized therapy and provide vital audio and visual feedback to patients.
MindMotion GO’s full-body motion capture technology and accompanying hand dexterity hardware allow therapists to monitor each patient’s movements, providing a tactical level of support that is similar to being present physically with them.
Rehabilitation DTx is
MindMaze released its roadmap for the commercial product portfolio and clinical pipeline on April 15, 2021. MindMaze is undoubtedly at the forefront of developing innovative digital neurotherapeutics solutions (DTx).
This platform approach combines highly engaging, serious game-based software with tailored smart peripherals that target both neurorehabilitation and neuro-restoration.
MindMaze’s Rehab DTx platform, and telerehabilitation services are both reimbursed in the U.S. as well as across Europe. They have been proven to be beneficial for patients, providers, and payers.
They are available at top US institutions like Johns Hopkins University Hospital, Mt. Sinai Health Systems. It provides clinicians and therapists with AI-driven longitudinal performance data and serious games to optimize delivery and dosing while facilitating greater patient volumes.
Rehab DTx products were invaluable during the Covid-19 crisis. They have offered valuable benefits to patients both in-hospitals and in-clinics, allowing for more clinical staff and resources as well as home-based care.
More than ten thousand patients have benefited from MMHC’s FDA-approved and CE-marked products in 20 countries.
NeuroDTx’s strong clinical evidence pipeline
Neuro DTx is a platform that promotes the repair and reorganization of the nervous system during diseases, injuries, or aging. It also provides protocolized software that doctors can prescribe.
The company has been working closely with leading academic institutions to build a strong pipeline of clinical evidence. MMHC anticipates that in the next few decades, it will have at least three prescription digital therapeutic options for chronic stroke, PD, and aging/MCI.
Developing a universal platform to promote brain health
MindMaze also offers Neuro DTx and Rehab DTx solutions. MindMaze also offers smart peripherals, quantitative assessments, and motor and cognitive capacity tracking.
These data are then processed on an AI cloud-based platform and sent back to clinicians and patients. Combining cutting-edge neuroscience with AI-powered engineering and immersive games-based activities increases the potential for recovery in patients suffering from debilitating neurological conditions.
It also reduces the effects of aging on cognition, movement, and cognition.
An additional 125 million raised to accelerate expansion
MindMaze has closed a USD 125 million round of investment on October 7, 2021. This will be used to continue growing its SaaS-based digital neuroscience platform.
AlbaCore Capital Group provided the financing. They are one of Europe’s most experienced specialist investors, focusing on both public and private corporate credit markets.
MindMaze plans to use the proceeds to accelerate market access and commercialization of its approved and paid neuro-rehabilitation platform, especially in North America and Europe.
It will also expand its neuro-restorative portfolio by further system development and clinical trials in other indications, including multiple sclerosis, acute stroke, Parkinson’s disease, Alzheimer’s disease, traumatic brain injuries, multiple sclerosis, multiple sclerosis, and aging.
MindMaze’s investment will help to strengthen one of Europe’s most prominent HealthTech leaders. It is one of three top-ranked private capital raises in Continental European digital healthcare.
MindMaze Partners With UK Hospital for Digital Therapy Solution for Brain Repair
MindMaze joined the Royal Buckinghamshire Hospital (RBH), based in Aylesbury, to launch its MindPod, a platform that targets cognitive and motor rehabilitation in stroke patients.
MindPod is the first-ever immersive neuro-animation experience. It’s a unique form of location-based digital therapy that focuses on brain healing through intense and complex exploratory movements.
MindPod is an immersive, location-based animated gaming experience that uses customized sound, lighting, and movement tracking. It is a neurorestorative treatment that has been FDA-listed and CE-Marked. It was developed by Johns Hopkins University School of Medicine’s Department of Neurology.
MindMaze’s U.K. first MindPod hospital installation, RBH, is based on a recent study that found that it is twice the effectiveness of traditional rehabilitation in the upper legs during the sub-acute stage.
MindPod employs universal principles of brain healing; ongoing trials are using the same immersive space for Parkinson’s disease (traumatic brain injury), dementia, and healthy aging. This demonstrates its potential for wider use in neurological disease or injury.
MindPod has been the subject of numerous clinical trials around the world, including six studies that examined its effectiveness in stroke recovery. MindPod recently showed twice the effectiveness in treating sub-acute strokes than conventional rehabilitation.
MindPod has been successfully piloted in a community setting to improve the cognitive and functional well-being of the elderly. A clinical trial continues to examine the impact of MindPod on Parkinson’s disease motor and cognitive function.
The U.S. Department of Defense-funded another study to evaluate MindPod’s effectiveness in slowing the progression of dementia in older patients with traumatic brain injuries.
Researchers are also investigating its potential use for motor recovery in cervical spinal cord injury, mild-to-moderate Multiple Sclerosis, and hands and fingers.